KR900015718A - 골관절염 치료제 - Google Patents

골관절염 치료제 Download PDF

Info

Publication number
KR900015718A
KR900015718A KR1019900006105A KR900006105A KR900015718A KR 900015718 A KR900015718 A KR 900015718A KR 1019900006105 A KR1019900006105 A KR 1019900006105A KR 900006105 A KR900006105 A KR 900006105A KR 900015718 A KR900015718 A KR 900015718A
Authority
KR
South Korea
Prior art keywords
therapeutic agent
compound
physiologically acceptable
acyl group
group
Prior art date
Application number
KR1019900006105A
Other languages
English (en)
Other versions
KR920004095B1 (ko
Inventor
후미히꼬 기무라
유따까 무까이다
고주 와따나베
Original Assignee
고다마 스니찌로
구레하 가가꾸 고교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고다마 스니찌로, 구레하 가가꾸 고교 가부시끼가이샤 filed Critical 고다마 스니찌로
Publication of KR900015718A publication Critical patent/KR900015718A/ko
Application granted granted Critical
Publication of KR920004095B1 publication Critical patent/KR920004095B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음.

Description

골관절염 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1(a) 및 1(b)도는 인간의 활막 세포내에서의 IL-1 생산에 미치는 ACP, PAL 및 PAC의 억제 활성에 관한 실험결과 그래프(값은 막대 그래프상에 평균값±표준오차(n=3)의 형태로 나타냄)
제2(a) 및 2(b)도는 인간의 단핵세포에서의 IL-1 생산에 미치는 ACP, 3,4-디-n-프로피오닐옥시벤질리덴 디-n-프로피오네이트, 3,4-디-n-도데카노일옥시벤질리덴 디-n-도데카노에이트, 3,4-디-n-옥타데카노일옥시벤질리덴, 디-n-옥타데카노에이트, 3,4-디벤조일옥시벤질리덴, 디벤조에이트, PAL 및 PAC의 억제효과에 관한 실험결과 그래프(값은 막대 그래프상에 평균값±표준오차(n=3)의 형태로 나타냄).
제3도는 인간의 연골세포 배양물로부터의 IL-1 분비에 미치는 ACP, PAL 및 PAC의 억제효과에 관한 실험결과 그래프(값은 막대 그래프상에 평균값±표준오차(n=3)의 형태로로 나타냄).

Claims (8)

  1. 하기 일반식(1)의 화합물 1 이상을 함유하는 골관절염 치료제 :
    상기시에서, R은 수소 원자 또는 아실기이고; X는 CHO, COOH, 생리학적으로 허용되는그의 염, 또는 CH(OR')2기이고, 여기서 R' 는 아실기를 나타낸다.
  2. 제1항에 있어서, 상기 R 과 R'가 동일한 아실기를 나타내는 치료제.
  3. 제1항에 있어서, 상기 R 과 R'가 독립적으로 각기 다른 아실기르 나타내는 치료제.
  4. 제1항에 있어서, 상기 R 과 R'가 각각및를 나타내고, 여기서 Y와 Y'는 독립적으로 탄소수 1 내지 18의 직쇄 알킬기 또는 방향족 잔기를 나타내는 치료제.
  5. 제1항에 있어서, 상기 생리학적으로 허용되느 염이 나트륨염인 치료제.
  6. 제1항에 있어서, 상기 화합물이 3,4-디알카노일옥시벤질리덴 디알카노에이트인 치료제.
  7. 제1항에 있어서, 상기 화합물이 3,4-디히드록시벤즈알데히드인 치료제.
  8. 제1항에 있어서, 상기 화합물이 3,4-디히드록시벤조산 및 생리학적으로 허용되는 그의 염인 치료제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900006105A 1989-04-28 1990-04-26 골관절염 치료제 KR920004095B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11014889 1989-04-28
JP110148 1989-04-28
JP2034065A JPH085780B2 (ja) 1989-04-28 1990-02-15 変形性関節症治療剤
JP34065 1990-02-15
JP36064/90 1990-02-15

Publications (2)

Publication Number Publication Date
KR900015718A true KR900015718A (ko) 1990-11-10
KR920004095B1 KR920004095B1 (ko) 1992-05-25

Family

ID=26372861

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900006105A KR920004095B1 (ko) 1989-04-28 1990-04-26 골관절염 치료제

Country Status (9)

Country Link
US (1) US4997850A (ko)
EP (1) EP0395441B1 (ko)
JP (1) JPH085780B2 (ko)
KR (1) KR920004095B1 (ko)
AU (1) AU614227B2 (ko)
CA (1) CA2015475C (ko)
DE (1) DE69016821T2 (ko)
DK (1) DK0395441T3 (ko)
ZA (1) ZA902975B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273033A (en) * 1991-09-19 1993-12-28 Murray Electronics Associates Limited Partnership Electrical stimulation for treatment of osteoarthritis
US5388644A (en) * 1993-02-08 1995-02-14 Buckman Laboratories International, Inc. Application of N,N-dialkylamides to reduce precipitation of asphalt from crude oil
JPH0725761A (ja) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd 軟骨保護剤
GB9400047D0 (en) * 1994-01-04 1994-03-02 Norsk Hydro As Pharmaceutical compositions
US6025401A (en) * 1996-11-15 2000-02-15 The Picower Institute For Medical Research Method and agents for inhibiting protein aging
EP1443915B1 (en) * 2001-11-16 2006-06-21 Cutanix Corporation Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) * 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US20040162582A1 (en) * 2003-02-13 2004-08-19 Hmt High Medical Technologies Ag Treatment of osteoarthritis
EP1622554A4 (en) * 2003-05-15 2008-01-02 Bioform Medical Inc COMPOSITIONS CONTAINING A COMBINATION OF A PHARMACEUTICAL AGENT OR A COSMETIC AGENT AND AN OXY-GROUP-WEARING AROMATIC ALDEHYDE
WO2006009836A2 (en) 2004-06-17 2006-01-26 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
EP2927241A1 (en) 2005-09-20 2015-10-07 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
US8263069B2 (en) 2008-12-31 2012-09-11 Johnson Lanny L Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions
SG10202009963PA (en) 2011-01-07 2020-11-27 Allergan Inc Melanin modification compositions and methods of use
US10398664B2 (en) 2013-05-01 2019-09-03 Lanny Leo Johnson Methods of diagnosing and treating infected implants
US10016380B2 (en) 2013-05-01 2018-07-10 Lanny Leo Johnson Antimicrobials and methods of use thereof
US9498413B2 (en) 2013-05-01 2016-11-22 Lanny Leo Johnson Antimicrobials and methods of use thereof for wound healing
US9968623B2 (en) 2013-08-29 2018-05-15 Lanny Leo Johnson Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent
US11925656B2 (en) 2014-11-05 2024-03-12 Lanny Leo Johnson Biological total joint replacement
US11980635B2 (en) 2014-11-05 2024-05-14 Lanny Leo Johnson Methods of oral administration of protocatechuic acid for treating or reducing the severity of a joint injury or disease
WO2018204621A1 (en) * 2017-05-03 2018-11-08 Johnson Lanny Leo Compositions including protocatechuic acid for the prevention or treatment of osteoarthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54160740A (en) * 1978-06-09 1979-12-19 Takeda Chem Ind Ltd Anti-fibrotic agent
JPS6026370B2 (ja) * 1978-10-09 1985-06-24 寶酒造株式会社 制癌剤
JPS5883619A (ja) * 1981-11-11 1983-05-19 Kureha Chem Ind Co Ltd 抗炎症剤
JPS58183619A (ja) * 1982-04-21 1983-10-26 Itochu Shiryo Kk 家禽類の発育促進方法
JPS59196818A (ja) * 1983-04-25 1984-11-08 Kureha Chem Ind Co Ltd 腎炎治療剤
US4758591A (en) * 1983-12-26 1988-07-19 Kureha Kagaku Kogyo Kabushiki Kaisha Dialkanoyloxybenzylidene dialkanoate
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives

Also Published As

Publication number Publication date
US4997850A (en) 1991-03-05
DE69016821D1 (de) 1995-03-23
DE69016821T2 (de) 1995-08-17
EP0395441B1 (en) 1995-02-15
JPH085780B2 (ja) 1996-01-24
JPH0372418A (ja) 1991-03-27
CA2015475A1 (en) 1990-10-28
AU5375690A (en) 1990-11-01
EP0395441A2 (en) 1990-10-31
KR920004095B1 (ko) 1992-05-25
ZA902975B (en) 1991-01-30
AU614227B2 (en) 1991-08-22
DK0395441T3 (da) 1995-06-26
CA2015475C (en) 1995-04-18
EP0395441A3 (en) 1992-03-25

Similar Documents

Publication Publication Date Title
KR900015718A (ko) 골관절염 치료제
FR2392971A1 (fr) Derives de l'acide prostanoique, leur preparation et medicament contenant ces substances
FR2414039A1 (fr) Derives de prostacycline, leur procede de preparation et leurs applications en therapeutique
BR9913680A (pt) Composições terapêuticas (ii)
FR2427320A2 (fr) Derives d'acides phenoxyalkylcarboxyliques et leur application en therapeutique
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
KR890016966A (ko) 신규 항바이러스제
KR920700201A (ko) 신규 1α-히드록시비타민D 2 에피머 및 유도체
BE900345A (fr) Composition pharmaceutique ophtalmiques a base d'un derive d'acide phenylacetique.
KR890003382A (ko) 항 비루스성 화합물
FR2397403A1 (fr) Nouveaux derives de 1-acyl 2-cyano-aziridine, procede pour leur preparation et compositions pharmaceutiques contenant ces composes
KR870005986A (ko) 방향족 티오에테르 및 이의 제조방법
KR970025615A (ko) 암 전이 억제제
ES2064461T3 (es) Derivados de xantina, procedimiento para su preparacion y composicion farmaceutica.
KR950000663A (ko) 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질
FR2418797A1 (fr) Nouveaux derives heterocycliques d'acide acetique, leur procede de preparation et leur application en therapeutique
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
ATE41772T1 (de) Polymethoxybenzyl-piperazin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen.
KR910700230A (ko) 신규 히드록실아민 유도체
BE902796A (fr) Ester d'acetyl carnitine, sa preparation et son utilisation.
KR880007080A (ko) 제약학적 생성물
KR880009654A (ko) 아세트알데히드의 독성을 감소시키는 조성물 및 방법
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR920000715A (ko) 신규의 n- 벤질-n1- 페닐-및- 펜알킬- 티오우레아류
KR890009401A (ko) 바이러스를 억제시키는 방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19970520

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee